A Phase 3 interventional study of trastuzumab and Chemotherapy in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 35 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-24.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 198th largest by enrollment of the 366 interventional ones that give a count, is one of 19 that started in 2007, is one of 60 in phase 3, and was the 93rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 19 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 27 under way, 13 of them phase 3. Of 194 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 127th largest by enrollment of the 170 interventional ones that give a count, is one of 12 that started in 2007, is one of 61 in phase 3, and was the 24th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 2 arm study will compare the efficacy and safety of continuation or discontinuation of Herceptin treatment in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic breast cancer whose condition has progressed on 1st line chemotherapy plus Herceptin. Patients will be randomized either to continue or discontinue Herceptin treatment (2mg/kg iv infusion weekly, or 6mg/kg iv infusion every 3 weeks) while receiving 2nd line chemotherapy of the investigator's choice. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chemotherapy, schedule and dose at the investigator's discretion.
Drug: Chemotherapy
Trastuzumab, at the investigator's discretion, either 2 milligrams per kilogram (mg/kg) intravenous (i.v.) every 7 days or 6 mg/kg i.v. every 3 weeks. Chemotherapy, schedule and dose at the investigator's discretion.
Drug: trastuzumab · Drug: Chemotherapy
2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
Also known as: Herceptin
Schedule and dose at the investigator's discretion
Progression-Free Survival (PFS) - Percentage of Participants With an Event
PFS was defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Participants were censored at the last tumour evaluation.
Time frame: Baseline (BL) and every 8 weeks thereafter
Progression-Free Survival - Time to Event
The median time from randomization to PFS event. Participants were censored at the last tumour evaluation.
Time frame: BL and every 8 weeks thereafter
Overall Survival (OS) - Percentage of Participants With an Event
OS was defined as the time from randomization to the date of death from any cause. Participants were censored at the last contact date at which the participant was known to be alive.
Time frame: BL and every 8 weeks thereafter
Overall Survival - Time to Event
The median time from randomization to OS event. Participants were censored at the last contact date at which the participant was known to be alive.
Time frame: BL and every 8 weeks thereafter
Percentage of Participants by Best Overall Response (BOR)
BOR was defined as the best objective response observed during the treatment period according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR): disappearance of all target lesions (TLs), with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 millimeters (mm). Partial response (PR): at least a 30 percent (%) decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. Progressive disease (PD): at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. Stable disease (SD) was defined as neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: BL and every 8 weeks thereafter
Percentage of Participants With a Best Overall Response of CR or PR
BOR was defined as the best objective response observed during the treatment period according to RECIST version 1.1. CR: disappearance of all TLs, with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 mm. PR: at least a 30% decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. PD: at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. SD: neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: BL and every 8 weeks thereafter
| Milestone | Chemotherapy Alone | Chemotherapy Plus (+) Trastuzumab |
|---|---|---|
| Started | 29 | 29 |
| Completed | 0 | 0 |
| Not completed | 29 | 29 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Disease progression | 16 | 18 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Other | 6 | 4 |
| Withdrew: Protocol violation | 0 | 1 |
PFS was defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Participants were censored at the last tumour evaluation.
| percentage of participants | Chemotherapy Alone | Chemotherapy + Trastuzumab |
|---|---|---|
| Progression-Free Survival (PFS) - Percentage of Participants With an Event | 58.6 | 58.6 |
The median time from randomization to PFS event. Participants were censored at the last tumour evaluation.
| months | Chemotherapy Alone | Chemotherapy + Trastuzumab |
|---|---|---|
| Progression-Free Survival - Time to Event | 9.7 (5.5 to 18.9) | 9.4 (6.7 to 12.0) |
OS was defined as the time from randomization to the date of death from any cause. Participants were censored at the last contact date at which the participant was known to be alive.
| percentage of participants | Chemotherapy Alone | Chemotherapy + Trastuzumab |
|---|---|---|
| Overall Survival (OS) - Percentage of Participants With an Event | 55.2 | 34.5 |
The median time from randomization to OS event. Participants were censored at the last contact date at which the participant was known to be alive.
| months | Chemotherapy Alone | Chemotherapy + Trastuzumab |
|---|---|---|
| Overall Survival - Time to Event | 19.1 (17.0 to 32.7) | 26.7 (14.0 to NA) |
BOR was defined as the best objective response observed during the treatment period according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR): disappearance of all target lesions (TLs), with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 millimeters (mm). Partial response (PR): at least a 30 percent (%) decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. Progressive disease (PD): at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. Stable disease (SD) was defined as neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Chemotherapy Alone | Chemotherapy + Trastuzumab |
|---|---|---|
| CR | 0 | 10.3 |
| PR | 27.6 | 20.7 |
| SD | 24.1 | 24.1 |
| PD | 17.2 | 13.8 |
| Not Evaluated | 31.0 | 31.0 |
BOR was defined as the best objective response observed during the treatment period according to RECIST version 1.1. CR: disappearance of all TLs, with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 mm. PR: at least a 30% decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. PD: at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. SD: neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Chemotherapy Alone | Chemotherapy + Trastuzumab |
|---|---|---|
| Percentage of Participants With a Best Overall Response of CR or PR | 27.6 (12.7 to 47.2) | 31.0 (15.3 to 50.8) |
Collected over Adverse events (AEs) were recorded throughout the study. Drug-related serious AEs (SAEs) were collected, regardless of the time elapsed from last study treatment administration, even if the study had been closed.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chemotherapy Alone | — | 4/26 (15.4%) | 26/26 (100%) |
| Chemotherapy + Trastuzumab | — | 1/28 (3.6%) | 26/28 (92.9%) |
| Event | Chemotherapy Alone | Chemotherapy + Trastuzumab |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/26 | 0/28 |
| General MalaiseGeneral disorders | 1/26 | 0/28 |
| Acute renal failureRenal and urinary disorders | 1/26 | 0/28 |
| Hospitalisation for intrapleuric chemotherapy and thoracentesisGeneral disorders | 1/26 | 0/28 |
| Gastric volvulusGastrointestinal disorders | 0/26 | 1/28 |
| Event | Chemotherapy Alone | Chemotherapy + Trastuzumab |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 16/26 | 9/28 |
| LeukopeniaBlood and lymphatic system disorders | 13/26 | 7/28 |
| Other - unspecifiedGeneral disorders | 8/26 | 9/28 |
| NauseaGastrointestinal disorders | 8/26 | 1/28 |
| AstheniaGeneral disorders | 7/26 | 1/28 |
| AnemiaBlood and lymphatic system disorders | 5/26 | 1/28 |
| FeverGeneral disorders | 5/26 | 3/28 |
| VomitingGastrointestinal disorders | 5/26 | 1/28 |
| DiarrheaGastrointestinal disorders | 2/26 | 5/28 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/26 | 3/28 |
Intent-to-treat (ITT) population: all randomized participants.
| Age, Continuous(years) | Chemotherapy Alone | Chemotherapy + Trastuzumab | Total |
|---|---|---|---|
| Median | 59 (38 to 81) | 57 (39 to 82) | 58 (38 to 82) |
| Sex: Female, Male(Participants) | Chemotherapy Alone | Chemotherapy + Trastuzumab | Total |
|---|---|---|---|
| Female | 29 | 29 | 58 |
| Male | 0 | 0 | 0 |
The record gives a start of Apr 2007, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab